Posted by Michael Wonder on 11 Jun 2024
Calico Life Sciences announces that fosigotifator (ABBV-CLS-7262) for vanishing white matter disease has been selected for the FDA START pilot program
7 June 2024 -- Calico Life Sciences today announced that its investigational eIF2B activator fosigotifator (ABBV-CLS-7262) has been accepted into the US FDA Support for clinical Trials Advancing Rare disease Therapeutics (START) pilot program.
Fosigotifator is being developed by Calico and AbbVie pursuant to their 2014 collaboration as a potential treatment for vanishing white matter disease.
